BioSpace News Archive

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that management will present at the RBC Global Healthcare Conference on Tuesday, May 19, 2020 at 9:10 a.m. ET. The audio portion of management’s live and archived webcast can be accessed from https://www.veracast.com/webcasts/rbc/healthcare2020/96103453385.cfm . The archived webcast will be available one hour after t

- Dry Eye Disease Phase 2 Study Remains on Track - Data Anticipated in 4Q20 - $89 Million in Cash at March 31, 2020 - Teleconference and Webcast to be held on May 12, 2020

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that its COVID-19 at-home collection test kit is now being offered to individuals nationwide who have symptoms consistent with COVID-19 infection and individuals without symptoms who may have been exposed to the virus.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced it will host a conference call and webcast to provide a business update on Tuesday, May 19, 2020 at 4:30 p.m. EDT.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 11:40 AM ET. A live webcast of the presentation can be accessed through the Investors section

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced an upcoming full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib. Dr. Dedee Murrell, professor and Head of the Department of Dermatology at The St. George Hospital Clinic School, University of New South Wales in Sydney,

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced positive results from a consumer product test evaluating the efficacy of its shampoo on dermatitis and dandruff. Kane Biotech’s shampoo was developed based on research indicating that the persistence of microbial biofilm may be linked with aggravating the symptoms associated with atopic dermatitis, seborrheic dermatitis (also known as eczema) and dandruff. The

Homology Medicines, Inc., a genetic medicines company, announced the presentation of data at the American Society of Gene & Cell Therapy 23rd Annual Meeting.

AIDS Healthcare Foundation demanded that remdesivir, the newly approved drug for treating COVID-19, be priced at no more than one U.S. dollar per dose.